PIPELINE









Lead Transplant Product Candidates



MDR-101:

Cellular immunotherapy containing a unique formulation of organ donor-derived CD34+ hematopoietic stem and progenitor cells and CD3+ T cells; capable of inducing mixed chimerism and persistent donor-specific immune tolerance in HLA-matched, living-donor kidney transplant recipients; intended to preserve transplant organ function and eliminate the need for life-long, costly, and toxic anti-rejection immunosuppressive drugs; and investigational therapy in Medeor's Phase 3 study MDR-101-MLK

MDR-102:

Cellular immunotherapy containing a unique formulation of organ donor-derived CD34+ hematopoietic stem and progenitor cells and CD3+ T cells; capable of inducing mixed chimerism and persistent donor-specific immune tolerance in HLA-mismatched, living-donor kidney transplant recipients; intended to improve transplant organ function and minimize the need for life-long, costly, and toxic anti-rejection immunosuppressive drugs; and investigational therapy in Medeor's planned Phase 2b study MDR-102-mMLK

  MDR-103:

Cellular immunotherapy based on MDR-101; intended for delayed (i.e., months and potentially years post-transplant) infusion and induction of mixed chimerism followed by persistent donor-specific immune tolerance in living-donor kidney transplant recipients; and investigational therapy in Medeor's planned Phase 2 study MDR-103-L2K